February 9, 2017 02:45 PM GMT

## UPDATE

## Lupin Ltd.

# F3Q In Line: Medium-term Pipeline Delivery Keeps Us OW

Industry ViewIn-Line

© Price Target Rs1,846.00

New approvals in the US remain key to offset erosion from gFortamet/Glumetza. This should commence towards the end of F17 and then pick up in F18 and F19. This, along with steady EM growth, improving pipeline (with inhalers, injectables, specialty) and reasonable valuations, drive our OW rating.

Business outlook: Management expects to launch over 25 products in the US over the next 12 months, which could offset erosion in gGlumetza/Fortamet. Some of these niche launches include drugs, such as gMinastrin, gEpzicom, bupropion XL, potassium CL, gVigamox, etc. In addition, FY18 should see a good number of controlled substances (ramp up in F19) and derma launches along with Gavis ramp up. Lupin has filed albuterol MDI (ProAir - brand size US\$3bn) and expect this to be 3-4 player market. gAdvair is on track for FY18 filing (Lupin expects to commence clinical trials, and has completed pivotal studies). Sevelamer/colesevelam products are delayed due to pending FDA queries. Lupin expects to respond to these in Q4FY17 and hopefully get approval in late FY18/early FY19. R&D productivity is gaining traction with significant higher filing in complex generic space. It expects to file 30 ANDA in FY17. It is seeing high single-digit price erosion in US market.

Other Concall highlights: US business improved sequentially due to ramp up in gGlumetza, Methargine (US\$4mn/mt) and 3-4 small launches. It expects Sun and Teva to enter the market in the next 12 months. Entry of AG (authorized generics) should overall expand generic market. gFortamet faced some price erosion/ share loss due to Mylan's entry, full impact of which will be visible in Q4. Aurobindo filing will have a 30-month stay (Lupin expects brand to litigate). Indian business should grow ~15% in medium to long term but GST could create some disruption in FY18. Japan business (including Shionogi) should see double-digit growth in FY18. Company expects tax rate for FY17 to be c.26-28%. Capex to be Rs19bn (R&D site in Pune, Japan manufacturing) in FY17 and Rs13-14bn in FY18.

**F3Q Broadly In Line:** Lupin reported sales of Rs44.8bn, up 36.4% yoy (4.5% qoq), driven by US (up 8.9% qoq due to gGlumetza) and India business (up 12% yoy despite demonetization). Japan, EMEA, LATAM markets were up 21%/17%/32%, respectively. OPM expanded 330 bps yoy (320bps qoq) to 27.1% due to better product mix and FX impact of Rs270mn (across multiple line items). All this along with higher other income of Rs1035mn led to net profit of Rs6.3bn (down 4.4% qoq/up 20.8% yoy, vs. MSe of Rs6.5bn).

MORGAN STANLEY INDIA COMPANY PRIVATE LIMITED+

#### Sameer Baisiwala, CFA

**EQUITY ANALYST** 

Sameer.Baisiwala@morganstanley.com +91 22 6118-2214

#### Vaibhav Dusad

RESEARCH ASSOCIATE

Vaibhav.Dusad@morganstanley.com +91 22 6118-2215



Morgan Stanley appreciates your support in the 2017 Institutional Investor All-Asia Research Team Survey. Voting will open mid-February 2017.

#### Lupin Ltd. (LUPN.NS, LPC IN)

India Healthcare / India

Stock Rating	Overweight
Industry View	In-Line
Price target	Rs1,846.00
Up/downside to price target (%)	24
Shr price, close (Feb 9, 2017)	Rs1,491.35
52-Week Range	Rs1,911.90-1,280.00
Sh out, dil, curr (mn)	451
Mkt cap, curr (mn)	Rs672,002
EV, curr (mn)	Rs740,222
Avg daily trading value (mn)	Rs0

03/16	03/17e	03/18e	03/19e
50.45	66.48	77.08	90.74
-	-	-	-
49.25	63.56	73.75	84.92
142,08	170,75	194,75	222,50
5	8	9	5
37,535	47,281	53,336	63,509
22,707	29,954	34,733	40,886
29.3	22.4	19.3	16.4
6.1	6.1	6.1	6.1
24.1	15.0	18.9	21.8
25.6	27.3	31.6	37.2
19.6	15.3	13.7	11.6
0.5	0.4	0.4	0.4
(10.1)	6.7	3.9	4.8
61.8	47.3	53.5	59.7
	50.45 49.25 142,08 5 37,535 22,707 29.3 6.1 24.1 25.6 19.6 0.5 (10.1)	50.45 66.48 49.25 63.56 142,08 170,75 5 8 37,535 47,281 22,707 29,954 29.3 22.4 6.1 6.1 24.1 15.0 25.6 27.3 19.6 15.3 0.5 0.4 (10.1) 6.7	50.45 66.48 77.08

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare

- § = Consensus data is provided by Thomson Reuters Estimates
- e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.



# Results Summary

Exhibit 1: Results Summary

(Rs mn)	F3Q17	F3Q16	%chg	F2Q17	%chg
(period ending)	Dec-16	Dec-15	YoY	Sep-16	QoQ
Sales (Net)	44,049	33,503	31.5%	42,112	4.6%
Other Operating Income	779	1,973	-60.5%	793	-1.7%
Total Revenues	44,829	35,477	26.4%	42,905	4.5%
Material Cost	13,016	11,232	15.9%	12,429	4.7%
Staff Costs	7,312	5,434	34.5%	7,124	2.6%
R&D Expenditure	5,682	3,916	45.1%	5,716	-0.6%
Other Expenditure	12,343	10,349	19.3%	13,072	-5.6%
Total Expenditure	32,670	27,015	20.9%	32,624	0.1%
Operating profit	12,158	8,461	43.7%	10,281	18.3%
Other Income	1,036	664	56.0%	271	282.1%
EBITDA	13,194	9,125	44.6%	10,552	25.0%
Interest (Net)	459	99	364.4%	263	74.6%
Depreciation	2,309	1,216	89.9%	2,112	9.3%
PBT and Extra-ordinaries	10,426	7,811	33.5%	8,177	27.5%
Tax	4,095	2,557	60.1%	1,589	157.6%
Core PAT	6,331	5,254	20.5%	6,587	-3.9%
Minority interest and share of lo	(0)	13	-101.6%	(34)	NM
Reported PAT	6,331	5,241	20.8%	6,622	-4.4%
GPM	71.0%	68.3%	2.6%	71.0%	-0.1%
OPM	27.1%	23.9%	3.3%	24.0%	3.2%
NPM	14.1%	14.8%	-0.7%	15.4%	-1.3%
Effective tax rate	39.3%	32.7%	6.5%	19.4%	19.8%

Lupin - Sales Breakdown

(Rs mn)	F3Q17	F3Q16	%chg YoY	F2Q17	%chg QoQ
Formulations	41,365	30,668	34.9%	39,194	5.5%
US (including IP)	21,755	13,805	57.6%	19,978	8.9%
EMEA (inc EU, South Africa)	2,555	2,187	16.8%	2,355	8.5%
India	9,912	8,860	11.9%	9,959	-0.5%
APAC (Japan)	5,601	4,634	20.9%	5,520	1.5%
LATAM	1,175	885	32.8%	986	19.2%
Rest of world	367	297	23.6%	396	-7.3%
API	2,684	2,835	-5.3%	2,919	-8.1%
Total net sales	44,049	33,503	31.5%	42,113	4.6%

Source: Morgan Stanley Research, Company Data

## Valuation

**Our price target is Rs1,846 is based on 22x Sep F18e EPS.** Our target multiple of 22x is in line with the average industry multiple over the past three years. We view this as appropriate, based on the following:

 Strengthening fundamentals (deepening product pipeline and global footprints), especially diversification into low-competition therapies, including oral contraceptives, ophthalmologics, dermatology and respiratory care; This document is being provided for the exclusive use of RAJIV PILLAI at LUPIN LTD.

# Morgan Stanley | RESEARCH



- Possibility of lower-risk generic competition in the branded product portfolio in the US market; and
- Good visibility of niche generic launches every year for the next two to three vears.

## Versus:

- Some contribution from slow-growth legacy therapies (anti-TBs, APIs, etc.) to its base business;
- EPS vulnerability to competition in the key US generic and branded portfolio and impact of customer consolidation; and
- Regulatory risk (FDA issues worsening at Goa and Mandideep sites) in EMs, especially India.



## **Disclosure Section**

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (BSE Registration No. INB011054237 and NSE Registration No. INB/INF231054231), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-372-2014) which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and/or PT Morgan Stanley Asia Indonesia and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

#### **Analyst Certification**

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Sameer Baisiwala. CFA.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

## Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

## Important US Regulatory Disclosures on Subject Companies

As of January 31, 2017, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: IPCA Laboratories.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Biocon Ltd, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddy's Lab, Glenmark Pharmaceuticals, Lupin Ltd., Sun Pharmaceutical Industries.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Biocon Ltd, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddy's Lab, Glenmark Pharmaceuticals, **Lupin Ltd.**, Sun Pharmaceutical Industries

Morgan Stanley & Co. LLC makes a market in the securities of Dr. Reddy's Lab, Sun Pharmaceutical Industries.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

#### STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

## **Global Stock Ratings Distribution**

(as of January 31, 2017)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.



	COVERAGE UI	NIVERSE	INVESTMEN	T BANKING CLIE	ENTS (IBC)	OTHER MAI INVESTMENT : CLIENTS (	SERVICES
STOCK RATING	COUNT	% OF	COUNT	% OF	% OF	COUNT	% OF
CATEGORY		TOTAL		TOTAL IBC	RATING		TOTAL
				(	CATEGORY		OTHER
							MISC
Overweight/Buy	1142	35%	280	42%	25%	566	36%
Equal-weight/Hold	1449	44%	300	45%	21%	706	45%
Not-Rated/Hold	62	2%	8	1%	13%	8	1%
Underweight/Sell	656	20%	76	11%	12%	279	18%
TOTAL	3,309		664			1559	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

#### **Analyst Stock Ratings**

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

#### **Analyst Industry Views**

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.


In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)





## Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

#### Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions. Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix. Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use

(http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy\_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy\_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation



of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City, in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Asia International Limited, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 1992062982) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Asia International Limited, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Indonesia by PT Morgan Stanley Asia Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin), in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating

This document is being provided for the exclusive use of RAJIV PILLAI at LUPIN LTD.

# Morgan Stanley | RESEARCH



to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P. Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

## INDUSTRY COVERAGE: India Healthcare

COMPANY (TICKER)	RATING (AS OF)	PRICE* (02/09/2017)
Sameer Baisiwala, CFA		
Biocon Ltd (BION.NS)	O (04/05/2016)	Rs1,089.80
Cadila Healthcare Ltd. (CADI.NS)	O (01/29/2016)	Rs366.25
Cipla Ltd. (CIPL.NS)	U (08/13/2013)	Rs587.65
Dr. Reddy's Lab (REDY.NS)	E (11/26/2015)	Rs3,023.10
GlaxoSmithKline Pharma (GLAXNS)	U (02/28/2013)	Rs2,735.85
Glenmark Pharmaceuticals (GLEN.NS)	O (12/13/2012)	Rs955.80
IPCALaboratories (IPCANS)	E (07/25/2014)	Rs527.95
Lupin Ltd. (LUPN.NS)	O (10/03/2006)	Rs1,491.35
Sun Pharmaceutical Índustries (SUN.NS)	E (12/21/2015)	Rs655.50

Stock Ratings are subject to change. Please see latest research for each company.

© 2017 Morgan Stanley

<sup>\*</sup> Historical prices are not split adjusted.